Tesamorelin: the only FDA-approved GHRH analog, and what that actually means

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, the 44-amino-acid peptide your hypothalamus uses to tell the pituitary to release growth hormone ^[2]. The molecule is modified at the N-terminus with a fatty-acid group, which slows proteolytic degradation enough to make the drug viable as a subcutaneous injection. It's still cleared relatively fast, meaningfully faster than small-molecule drugs, though substantially longer-lived than native GHRH, which is degraded almost instantly in circulation.

That's the whole drug class story in one paragraph. Tesamorelin is a GHRH receptor agonist. It tells your pituitary to do what it would do anyway, just more reliably.

The clinical consequence: pulsatile GH release, then a rise in IGF-1 from the liver and peripheral tissues. The pulsatility matters. Exogenous recombinant human growth hormone floods the system with continuous high levels, which is part of why long-term rhGH use carries an unfavorable risk profile in adults. Tesamorelin works upstream and lets the body's negative-feedback loops stay intact. At least in theory, that's the safety argument for the whole secretagogue category.

There are roughly three things people are talking about when they say "GHRH analog" or "GH secretagogue," and the distinctions matter clinically.

Tesamorelin is a stabilized GHRH analog. It binds the GHRH receptor, has a real half-life after subcutaneous injection, and is the only molecule in this family with FDA approval and phase 3 data.

Sermorelin is GHRH(1-29), the shortest active fragment of native GHRH ^[3]. It's the prototype. Approved by the FDA in the 1990s for pediatric growth hormone deficiency, then quietly withdrawn from the US market in the late 2000s, reportedly for commercial rather than safety reasons. It's still widely compounded for off-label adult use. Mechanism is the same. The half-life is shorter (minutes), and the clinical evidence base in adults is much thinner than tesamorelin's.

CJC-1295 is a longer-acting GHRH analog. The version often used in compounded peptide stacks is technically CJC-1295 without DAC (sometimes called modified GRF 1-29), with a much shorter half-life on the order of roughly 30 minutes. The "with DAC" version binds albumin and stretches the half-life to days, producing a sustained "bleed" of GH release that critics argue defeats the pulsatility argument entirely.

Ipamorelin is in a different class altogether. It's a ghrelin receptor agonist, a growth hormone secretagogue receptor (GHSR) agonist, not a GHRH analog. It triggers GH release through a parallel pathway, which is why it's commonly stacked with CJC-1295: activate two receptors, get a larger pulse.

So tesamorelin's claim to distinction isn't really mechanism. It's regulatory pedigree. It's the only molecule in this family that's been through a phase 3 program with imaging endpoints and a sBLA approval.

Tesamorelin was approved as Egrifta in November 2010 for HIV-associated lipodystrophy, sponsored by Theratechnologies ^[4]. The original formulation required daily reconstitution from two vials and refrigeration. Patients hated it.

The FDA later approved Egrifta SV, same drug, reformulated into a single vial that's stable at room temperature, with a lower dose shown to be bioequivalent to the original formulation.

Then in March 2025, Egrifta WR got the nod ^[5]. WR stands for weekly reconstitution. Patients still inject daily, but they only have to mix the vial once a week, and the injection volume is less than half what F4 required. Bioequivalence to the original formulation was established via standard PK studies.

One regulatory wrinkle worth understanding: federal law has, over time, shifted how certain peptide and protein drugs are classified, with some moving into the biologics category under rules governing how such products compete in the market. Tesamorelin moved with them. That administrative shift reshaped the entire compounding picture, which we'll come back to.

Tesamorelin binds GHRH receptors on the somatotroph cells of the anterior pituitary. The receptor is a G-protein coupled receptor that, when activated, triggers cAMP synthesis and the release of stored growth hormone. The release pattern is pulsatile, short bursts rather than sustained elevation, because the pituitary's own regulatory machinery is still in charge of the timing.

Released GH circulates to the liver, where it stimulates IGF-1 production. IGF-1 is the downstream mediator of most of GH's anabolic and metabolic effects, including lipolysis in visceral adipose tissue. VAT is the primary therapeutic target in lipodystrophy because it's metabolically active fat, the kind associated with insulin resistance and cardiovascular risk, rather than subcutaneous fat, which tesamorelin leaves largely alone.

IGF-1 also crosses the blood-brain barrier, with documented roles in neurogenesis and synaptic plasticity. That's the mechanistic basis for the cognitive trials we'll discuss, though "mechanistically plausible" and "clinically shown" are different bars.

HIV-associated lipodystrophy is a syndrome that emerged in the late 1990s alongside the first generation of antiretroviral therapy. The clinical picture: loss of subcutaneous fat in the face, arms, and legs, paired with accumulation of visceral fat in the abdomen. The newer integrase inhibitor regimens cause less of the lipoatrophy but still drive central fat gain in many patients.

This isn't cosmetic. Visceral adiposity in this population correlates with metabolic syndrome and cardiovascular events, plus quality-of-life decrements that patients consistently rate as severe. Before tesamorelin, there was no approved pharmacotherapy. Diet and exercise help, sometimes a lot, but the VAT compartment in this population is stubborn.

That's the indication the drug owns. Reducing excess abdominal fat in HIV-infected adults with lipodystrophy. No other indication is approved.

Two key phase 3 trials supported approval. Both were randomized, double-blind, placebo-controlled, with VAT measured by CT at baseline and at 26 weeks.

In the Falutz trial, patients on 2 mg daily tesamorelin showed real VAT reduction compared to placebo at 26 weeks. The reduction was roughly 15% from baseline ^[6], meaningful by the standards of pharmacologic body composition interventions, especially given that subcutaneous fat was not affected and lean mass was preserved.

Patients who continued past 26 weeks into a 52-week extension maintained the VAT reduction. Patients who crossed over to placebo regained VAT. That cross-over result is clinically important: tesamorelin is suppressive, not curative. Stop the drug, the fat comes back.

The second key trial replicated the VAT reduction and added improvement in waist circumference and patient-reported body image distress. A 2024 sub-analysis (Russo et al.) looked specifically at patients on integrase inhibitor regimens, the current standard of care, and found a meaningful VAT reduction versus an increase on placebo, plus a reduction in hepatic fat fraction by MR spectroscopy. Small sample. Real signal.

Across the program, IGF-1 rose into the upper-normal range in most patients. Triglycerides came down modestly. Glucose metabolism showed mixed signals. Some patients developed mild insulin resistance, which is consistent with what GH elevation does mechanistically, and which is why the label calls for fasting glucose monitoring.

This is where the story gets less clean.

The mechanism is general. GHRH agonism, GH release, IGF-1 elevation, preferential visceral lipolysis — none of that is HIV-specific. Clinicians have been extending the logic to non-HIV populations with central adiposity, NAFLD, or metabolic syndrome for years. The question is whether the clinical effect holds up outside the original trial population.

The NAFLD evidence is the most developed of the off-label cases. A phase 2 trial in HIV patients with NAFLD (NCT02196831, n=61) showed a meaningful reduction in liver fat fraction at 12 months ^[7]. A second phase 2 trial in non-HIV obese patients with NAFLD extended the question outside the HIV population. The early data are encouraging but not yet sufficient to support routine use, and there's no head-to-head against GLP-1 agonists, which have moved aggressively into this space with stronger evidence.

For general body composition in healthy adults, the evidence is weaker. There's no phase 3 trial of tesamorelin for "visceral fat in non-HIV adults." Clinicians who prescribe off-label for this purpose are extrapolating from the lipodystrophy data and the Baker et al. cognitive trial, which incidentally showed a meaningful reduction in body fat over the course of the study in healthy older adults.

For longevity broadly construed, tesamorelin sits alongside the rest of the GH-axis interventions, with the same unresolved question: does raising IGF-1 into the upper-normal range in older adults extend healthspan, or does it accelerate the cancer and metabolic risks that observational data link to higher IGF-1? The honest read is that we don't yet know. The Mendelian randomization data on IGF-1 and longevity are genuinely mixed.

The most cited piece of evidence here is Baker et al. (2012), published in a peer-reviewed neurology journal. It's a real RCT: 152 participants between 55 and 87, split between cognitively healthy older adults and people with mild cognitive impairment, randomized to 1 mg tesamorelin daily or placebo for 20 weeks ^[8].

The headline finding: tesamorelin improved executive function compared to placebo, in both the healthy and MCI groups. Verbal memory showed a similar pattern in the healthy cohort. Adverse events were mild, mostly skin reactions and joint pain, at rates consistent with the lipodystrophy program.

A follow-up MRS sub-study (Friedman et al., 2013) found tesamorelin increased brain GABA levels across multiple regions and decreased myo-inositol in the posterior cingulate, among other changes. Each of those shifts has a plausible neuroprotective interpretation, though "plausible" is doing real work in that sentence.

The limitations are large. One trial. Twenty weeks. No replication at scale. No data on whether the cognitive effects persist after discontinuation, or whether they translate to delayed dementia incidence over years. The MCI subgroup was small. The cognitive battery was sensitive but not the kind of endpoint that would support a label expansion.

So: a real, peer-reviewed signal, in a respectable journal, from a serious group. And nothing close to enough to call tesamorelin a cognitive intervention with established benefit. The trial is fourteen years old at this point and hasn't been replicated in a larger program. That's worth sitting with.

The approved dose is 2 mg subcutaneous daily, injected into the abdomen, with site rotation to minimize injection-site reactions. Egrifta SV's 1.4 mg dose is bioequivalent to the original 2 mg formulation. Egrifta WR uses the same daily injection but with weekly reconstitution and a smaller injection volume.

Off-label cognitive research used 1 mg daily, administered shortly before bedtime to align with the physiological GH pulse. Off-label NAFLD research has generally followed the approved 2 mg dose.

In real-world off-label clinical practice, dosing varies more than the trial literature would suggest. Some clinicians use the full 2 mg daily, some titrate up from 1 mg, some use intermittent schedules (five days on, two days off) on the theory that this preserves receptor sensitivity. None of the intermittent protocols have clinical trial support. They're extrapolated from older animal data on GHRH receptor desensitization.

Monitoring, when done properly, looks like this: baseline IGF-1, fasting glucose, lipid panel, and ideally CT or DXA for VAT quantification. Repeat IGF-1 and glucose every three months. The goal is to keep IGF-1 in the upper-normal range, not above it. Patients with IGF-1 levels that exceed the age-adjusted upper limit should have the dose reduced.

The Phase 3 program established a fairly clear adverse event profile. Injection site reactions (erythema, pruritus, occasional urticaria) were the most common, affecting a meaningful proportion of patients. Arthralgia and peripheral edema were the next most frequent, along with headache. Most of these were mild to moderate.

Hypersensitivity reactions occurred in about 3.6% of trial patients ^[9]. Serious adverse events were uncommon in the pooled analysis, occurring at low rates through the trial period.

The pharmacodynamic concerns are more interesting than the symptomatic ones. IGF-1 elevation, by design. Glucose tolerance can worsen modestly, which is biologically expected since GH antagonizes insulin action. This matters most in patients with pre-existing diabetes or prediabetes.

Hepatotoxicity has not emerged as a concern. Available drug-induced liver injury databases generally note no established association between tesamorelin and serum aminotransferase elevations or clinically apparent liver injury. That's a meaningfully clean liver safety record for a drug class that includes a lot of more concerning entries.

The longer-term unknowns are the ones to take seriously. Long-term IGF-1 elevation has uncertain implications for cancer risk, particularly in patients with personal or family history of malignancy. The trial program wasn't powered or duration-extended enough to detect those signals.

The FDA label is explicit on the absolute contraindications. Active malignancy: tesamorelin is contraindicated, full stop. Any disruption of the hypothalamic-pituitary axis, including hypophysectomy, hypopituitarism, pituitary tumor or surgical resection, head irradiation, or real head trauma. Pregnancy. Known hypersensitivity to tesamorelin or mannitol (an excipient).

The label also flags caution categories. History of malignancy without active disease requires individualized risk-benefit assessment. Diabetes mellitus requires closer glucose monitoring. Severe renal or hepatic impairment hasn't been formally studied, which is its own kind of warning.

Pediatric use isn't approved and data are limited. Tesamorelin shouldn't be used for weight management in the general population. That's stated explicitly on the label.

This is where the story gets unusual, and where a lot of the marketing surrounding compounded tesamorelin gets things wrong.

When the FDA reclassified most peptides as biologics in March 2020, tesamorelin moved with them. The legal consequence: 503A compounding pharmacies can't legally compound biologics. The 503A pathway exists for patient-specific compounding of drugs, not biologics.

503B outsourcing facilities have a separate framework, but they can only compound from bulk drug substances that appear on the FDA's 503B bulks list, or substances on the active drug shortage list. Tesamorelin is on neither.

The plain reading: legitimate compounding of tesamorelin in the United States is severely constrained under current FDA policy. NASPA, the regulatory body that tracks state pharmacy policy, has identified tesamorelin as a biologic for which 503A compounding is not permissible.

What does this mean for the patient or clinician trying to source tesamorelin? The brand-name pathway (Egrifta SV or now Egrifta WR) remains the regulatorily clean option, but it's also the expensive one, priced for an HIV indication served by insurance plans with specialty pharmacy benefits. Compounded tesamorelin marketed for longevity or body composition exists in the market, but the regulatory basis for that supply is uncertain at best. This is an area where enforcement policy is genuinely evolving, and where prescribers and patients should expect the landscape to shift.

The honest comparison goes like this.

Tesamorelin has the best clinical evidence of any GHRH analog. Phase 3 imaging endpoints, an FDA-approved indication, a documented adverse event profile, and a cognitive RCT in older adults that nobody else in this class has matched. The catch: narrow indication, biologic classification, complicated compounding picture, and a price point shaped by the HIV market.

Sermorelin has decades of clinical familiarity and a much simpler regulatory picture for compounding purposes. It's a short peptide fragment, not classified as a biologic in the same way, and is more readily available through traditional compounding pathways. The clinical evidence base in adult longevity use is mostly observational and small-trial. Half-life is short enough that dosing optimization gets harder.

Ipamorelin paired with CJC-1295 is the workhorse of the off-label peptide market for GH-axis support. The combination activates two pathways and produces a larger GH pulse than either alone. The clinical evidence is preliminary, mostly small, often industry-adjacent studies, and the long-term safety data in healthy adults essentially doesn't exist. The advantage is access and tolerability. Most patients find this stack easier to obtain and to tolerate than tesamorelin.

The choice isn't really clinical for most off-label patients. It's regulatory and economic. Tesamorelin is the molecule with the data. The other options are the molecules people actually end up using.

Inside the approved indication, the candidate profile is clear: an adult living with HIV, on stable antiretroviral therapy, with documented central adiposity and the metabolic or quality-of-life sequelae that go with it. The phase 3 data support the use, the regulatory pathway is clean, and the monitoring framework is established.

Outside the approved indication, the case is harder to make on current evidence. A patient with NAFLD and central adiposity might reasonably be considered, particularly if GLP-1 therapy isn't an option or hasn't worked. A patient with mild cognitive impairment whose family is asking about interventions might be discussed in the context of the Baker trial, with explicit acknowledgement that one 20-week RCT is not a treatment recommendation.

What tesamorelin isn't, on current data: a general anti-aging drug, a body composition optimizer for healthy adults, or a cognitive enhancer for the worried well. Nor is it a substitute for the lifestyle and metabolic interventions that have stronger evidence in each of those domains.

Tesamorelin is the most regulatorily legitimate peptide in the GHRH analog category. It has a real label, real phase 3 data, and a known safety profile in its approved population. The mechanism (pulsatile GH release through GHRH receptor agonism, with downstream IGF-1 elevation and preferential visceral lipolysis) is well characterized.

The off-label case is suggestive rather than established. The NAFLD data are promising and worth following. The cognitive data, anchored in one well-designed RCT from 2012, are interesting and unreplicated. The general longevity case rests on mechanistic plausibility, not outcomes evidence.

The regulatory picture for compounded tesamorelin is the part most patients and prescribers underestimate. Reclassification as a biologic in 2020 changed what's legal in ways that the marketing in this space hasn't fully caught up to. That's worth knowing before signing up for therapy from sources whose regulatory basis isn't obvious.

The cleanest read is that three assumptions deserve scrutiny: that the lipodystrophy data generalize cleanly to healthy adults, that IGF-1 elevation is benign at the duration most off-label users are considering, and that "compounded version of an FDA-approved drug" means the same thing it does for, say, semaglutide. It doesn't, here. The legal pathway is different.

The drug is real. The evidence is real where it exists. The space outside that evidence is wider than the marketing suggests.